Valerie Calvert

Research Assistant Professor

George Mason University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

WT EVs directly alter endothelial cell transcriptome, migration, barrier function, and tube formation. A, HPaMECs were treated with WT vs. HuR-KO EVs for 24 hours before RNA-seq and phenotypic assessment of migration, monolayer permeability, and tube formation. B, Volcano plot of differentially expressed genes in HPaMECs treated with PANC-1 HuR WT (blue, left) vs. HuR-KO (orange, right) EVs for 24 hours ( n = 3). C, Gene Ontology biological process analysis of the top seven pathways enriched in WT EV–treated and the top five pathways enriched in HuR-KO EV–treated HPaMECs ( n = 3). D, Transwell migration of HPaMECs treated with PANC-1 WT vs. HuR-KO EVs over 24 hours and quantified with crystal violet staining ( n = 3). Functional analysis of HPaMECs treated with media alone, PANC-1 WT, or HuR-KO EVs for 24 hours and monitored for ( E ) monolayer permeability quantified by dextran movement across the endothelial cell monolayer and ( F ) representative phase-contrast tube formation images with full field of view and region of interest (scale bar, 250 µm). G, Tube formation quantification for total tube length (px), total branching points, and total loops ( n = 3). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

HuR affects PDAC EV cargoes relating to endothelial cell functions. A, Schematic of EV isolation from PANC-1 WT vs. HuR-KO cells for EV validation, RNA-seq, and proteomics. B, Immunoblot of cell lysates (CL) and SEC fractions 3–6 (pre-EV), 7–10 (EV), and 11–14 (post-EV) from PANC-1 WT (HuR status +) and HuR-KO (HuR status −) cells. Blot probed for total protein (Ponceau), HuR, EV markers (TSG101 and CD81), and cell lysate control (cytochrome c). C, Electron microscopy validation of SEC fractions 7–10 (scale bar, 50 nm). D, Mean particle size and concentration normalized to final cell number measurements via fluorescent nanoparticle tracking analysis. P values were calculated using an unpaired two-tailed Student t test ( n = 4). E, RNA-seq volcano plot of differentially abundant genes in WT (blue, left) vs. HuR-KO (orange, right) EVs ( n = 4). F, RNA-seq pathway enrichment analysis highlighting the top nine enriched pathways in WT EVs (blue) and the top four enriched pathways in HuR-KO EV mRNA (orange). G, Volcano plot isobaric-labeling quantitative proteomics illustrating the differentially abundant proteins in WT (blue, left) vs. HuR-KO (orange, right) EVs ( n = 3). H, Proteomics pathway enrichment analysis highlighting the top nine enriched pathways in WT EVs (blue) and the top four enriched pathways in HuR-KO EV proteins (orange). ER, endoplasmic reticulum; ns, not significant; PDT, photodynamic therapy; OvCa, ovarian cancer; UPS, unfolded protein response.

Year:

2025

Pancreatic ductal adenocarcinoma (PDAC) tumors are hypovascular with collapsed and dysfunctional vessels that limit immunosurveillance and contribute to early metastatic events. However, current antiangiogenic therapies have failed in PDAC, highlighting the need to uncover the mechanisms by which cancer cells signal to endothelial cells to increase angiogenesis. Our lab has shown that the tumor-intrinsic RNA-binding protein human antigen R (HuR; ELAVL1 ) plays an important role in reshaping the tumor microenvironment by regulating the stability and translation of cell communication–encoding transcripts. We demonstrate that PDAC-intrinsic HuR influences endothelial cell function in the tumor microenvironment via extracellular vesicle (EV) signaling, an underexplored signaling axis in tumor progression. PDAC EVs contain an HuR-dependent mRNA and protein cargo related to endothelial cell function and angiogenesis. Treating endothelial cells with HuR wild-type (WT) EVs increased the expression of genes involved in barrier function and endothelial cell development and increased their migratory and tube-forming functions. In an immunocompetent mouse model of PDAC, we showed that HuR increased endothelial cell presence and sprouting, while decreasing intercellular adhesion molecule 1 (ICAM-1) expression. Using a genetic EV reporter, we found that ICAM-1 suppression in WT tumors occurred specifically in endothelial cells that had internalized WT EVs, suggesting that this signaling axis modulates endothelial cell behavior in vivo . Furthermore, administration of WT EVs rescued impaired HuR-knockout tumor growth, increased endothelial cell abundance, and decreased endothelial cell ICAM-1 expression. Collectively, our data reveal a novel role for HuR as a key mediator of EV signaling to endothelial cells, promoting angiogenesis while restricting endothelial cell leukocyte trafficking behavior. Significance: Targeting the abnormal pancreatic cancer vasculature remains a significant barrier to immunosurveillance and drug delivery. This study demonstrated that the tumor-intrinsic protein HuR regulates pancreatic cancer EVs, which, in turn, alters endothelial cell behavior. These findings reveal a novel mechanism by which tumor-intrinsic factors shape the vascular microenvironment and suggest that altering EV content could modulate endothelial cell function.

Year:

2025

Tumor-intrinsic HuR directly alters endothelial cell function via EV signaling. A, Schematic of the PalmGRET reporter labeling the inner leaflet of all membranes with GFP-nLuc via integration of a palmitoylation sequence. The construct for the PalmGRET EV reporter labels the inner leaflet of all cellular membranes and secreted membranous particles. B, PalmGRET-expressing cells produce GFP + EVs detected by fluorescent nanoparticle tracking analysis ( n = 3). C, Cell growth of PalmGRET-expressing KPC cells over 6 days. D, Immunoblot of cell lysates utilized for mouse studies probed for HuR, nLuc, and loading control vinculin. E, PalmGRET-expressing cells were orthotopically implanted into C57BL6 mice, and tumors were harvested at 14 days for flow cytometry. Levels of EV import (GFP MFI) in endothelial cells (CD45 − CD31 + ) were equal in WT and HuR-KO tumors ( n = 7). F, Total endothelial cell (CD45 − CD31 + ) presence as quantified by cells per gram of tumor in WT vs. HuR-KO tumors ( n = 7). G, ICAM-1 geometric mean surface expression of ICAM-1 in endothelial cells (CD45 − CD31 + ) of WT vs. HuR-KO tumors ( n = 7). H, ICAM-1 geometric mean surface expression (MFI) of ICAM-1 in endothelial cells of WT vs. HuR-KO tumors that have (GFP + ) or have not (GFP − ) imported PDAC EVs ( n = 7). P values were calculated using an unpaired two-tailed Student t test or an ordinary one-way ANOVA ( H only). *, P P P

Year:

2025

HuR WT EVs are tumor promoting and directly decrease ICAM-1 expression on endothelial cells. A, Schematic of EV isolation from KPC WT and HuR-KO cells via SEC. B, Immunoblot of cell lysates (CL) and SEC fractions 1, 7–10 (EV containing), and 14 from KPC WT (HuR status +) and HuR-KO (HuR status −) cells. Blot probed for total protein (Ponceau), HuR, EV markers (TSG101 and CD81), and cell lysate control (cytochrome c). C, Particle size concentration normalized to final cell number measurements via fluorescent nanoparticle tracking analysis. ( n = 4). D, Schematic of pancreatic orthotopic implantation of KPC KO cells into C57BL6 mice following intraperitoneal injection of WT vs. HuR-KO EVs every other day for 14 days and ( E ) tumor volume (mm 3 ) after 14 days (WT EV n = 6; HuR-KO EV n = 5). IF staining for ( F ) proliferation (Ki-67, magenta; n = 5), ( G ) endothelial cells (endomucin, magenta; WT EV n = 5 and HuR-KO EV n = 8), and ( H ) co-staining of endothelial cells (endomucin, magenta) and ICAM-1 (white; WT EV n = 6 and HuR-KO EV n = 7; scale bar, 100 µm). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

Endothelial cell abundance correlates with ELAVL1 expression, and endothelial cells import PDAC EVs. A, Correlation between ELAVL1 expression in PDAC cells and the presence of endothelial cells in publicly available patient single-cell RNA-seq. B, Within this cohort, a comparison of the endothelial cell percentage in patients with the highest and lowest quartiles of ELAVL1 expression. C, Representative images of HUVECs and HPaMECs treated with PKH67-labeled PANC-1 WT vs. HuR-KO EVs for 4 hours with stained nuclei (blue, DAPI) and cytoskeleton (phalloidin, red; scale bar, 50 µm). D, Relative cell area and levels of EV import [pixels (px)/cell area] of HUVECs and ( E ) HPaMECs after 4-hour EV treatment ( n = 3). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

Tumor-intrinsic HuR promotes endothelial cell recruitment and sprouting in PDAC tumors. A, Immunoblot of KPC WT and HuR-KO clones 6, 8, and 9 probed for HuR and loading control vinculin. B, KPC WT and HuR-KO cells were implanted orthotopically into the pancreas of immunocompetent C57BL6 mice, and tumor volume (mm 3 ) was measured after 14 days (WT n = 6; HuR-KO n = 10). C, KPC WT vs. HuR-KO IF staining for endothelial cells (endomucin, magenta) and nuclei (DAPI, teal; scale bar, 100 µm; WT n = 7 and HuR-KO n = 6). D, Ultrasound power Doppler imaging of orthotopic KPC WT and HuR-KO tumors to quantify percent vascularity at 13 days after implantation with tumor border in green and blood flow in red (WT n = 5; HuR-KO n = 4; scale bar, 1 mm). IF co-staining of KPC WT vs. HuR-KO tumors for ( E ) endothelial cells (endomucin, magenta) and sprouting (DLL4, white) and ( F ) endothelial cells (CD31, magenta) and ICAM-1 (white; scale bar, 100 µm; n = 5). P values were calculated using an unpaired two-tailed Student t test. *, P P P

Year:

2025

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic restoration of p16INK4A function with inhibitors of CDK4 and CDK6 (CDK4/6) has shown limited clinical efficacy in PDAC. Here, we found that concurrent treatment with both a CDK4/6 inhibitor (CDK4/6i) and an ERK–MAPK inhibitor (ERKi) synergistically suppresses the growth of PDAC cell lines and organoids by cooperatively blocking CDK4/6i-induced compensatory upregulation of ERK, PI3K, antiapoptotic signaling, and MYC expression. On the basis of these findings, a Phase I clinical trial was initiated to evaluate the ERKi ulixertinib in combination with the CDK4/6i palbociclib in patients with advanced PDAC (NCT03454035). As inhibition of other proteins might also counter CDK4/6i-mediated signaling changes to increase cellular CDK4/6i sensitivity, a CRISPR-Cas9 loss-of-function screen was conducted that revealed a spectrum of functionally diverse genes whose loss enhanced CDK4/6i growth inhibitory activity. These genes were enriched around diverse signaling nodes, including cell-cycle regulatory proteins centered on CDK2 activation, PI3K–AKT–mTOR signaling, SRC family kinases, HDAC proteins, autophagy-activating pathways, chromosome regulation and maintenance, and DNA damage and repair pathways. Novel therapeutic combinations were validated using siRNA and small-molecule inhibitor–based approaches. In addition, genes whose loss imparts a survival advantage were identified (e.g., RB1, PTEN, FBXW7), suggesting possible resistance mechanisms to CDK4/6 inhibition. In summary, this study has identified novel combinations with CDK4/6i that may have clinical benefit to patients with PDAC. Significance: CRISPR-Cas9 screening and protein activity mapping reveal combinations that increase potency of CDK4/6 inhibitors and overcome drug-induced compensations in pancreatic cancer.

Year:

2025

Supplemental Figure S1: IPA pathway highlights genes relevant to Organismal Death, Viral infection and Vasculogenesis for Untreated groups at Week 1 and Week 2 compared to Control Day 1. Significantly altered genes (2-fold change, p

Year:

2024

Supplemental Figure S3: IPA pathway highlights genes relevant to, Cell Migration, Angiogenesis and Morbidity or mortality for Treatment groups at Week 2 compared to Untreated Week 2. Significantly altered genes ([2-fold change, p

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (15)

Canping Chen

Oregon Health & Science University

UNITED STATES
View details

Iris Eke

Stanford University

UNITED STATES
View details

Rosalie C. Sears

Professor; Co-Director Brenden Colson Center for Pancreatic Care

Oregon Health & Science University

UNITED STATES
View details

Katelyn Byrne

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Mariaelena Pierobon

Professor of Applied Molecular Oncology

University of Sheffield

UNITED KINGDOM
View details

Kris Wood

Assistant/Associate/Full Professor (with tenure)

Duke University

UNITED STATES
View details

Zheng Xia

Associate Professor

University of Texas at Austin

UNITED STATES
View details

Jonathan R. Brody

Oregon Health & Science University

UNITED STATES
View details

Channing Der

Sarah Graham Kenan Distinguished Professor

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Andrew Waters

Assistant Professor

University of Cincinnati

UNITED STATES
View details

Adrienne D. Cox

University of North Carolina at Chapel Hill

UNITED STATES
View details

Hen Halamish

Oregon Health & Science University

UNITED STATES
View details

Kirsten Bryant

Research Assistant Professor

University of North Carolina

UNITED STATES
View details

Clint Stalnecker

Research Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jennifer Klomp

Assistant Professor

University of Michigan Health System

UNITED STATES
View details